Cellectis S.A. (CLLS) vs Coya Therapeutics (COYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Coya Therapeutics (COYA) has outperformed Cellectis S.A. (CLLS) over the past year, losing 20.9% versus a loss of 70.9%. Cellectis S.A. is the larger company by market cap ($125.9 million vs $117.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | COYA |
|---|---|---|
| Share price | $1.25 | $4.99 |
| Market cap | $125.90M | $117.05M |
| 1-day change | -6.72% | +1.63% |
| YTD return | -74.17% | -13.97% |
| 1-year return | -70.93% | -20.92% |
| 5-year return | -88.46% | — |
| EPS (TTM) | $-0.64 | $-1.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.48 | $7.75 |
| 52-week low | $1.22 | $3.71 |
| Distance from 52-week high | -77.19% | -35.61% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +326.40% | +204.81% |
| Average volume | 80.14K | 158.05K |
| Shares outstanding | 72.72M | 23.46M |
| Employees | 224 | 8 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COYA has outperformed CLLS by 50.0 percentage points over the past year.
- The two companies sit in different sectors: Cellectis S.A. in Health Care and Coya Therapeutics in Healthcare.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About Coya Therapeutics
COYA stock →Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Healthcare · Biotechnology · 8 employees
CLLS vs COYA FAQ
Which is bigger, Cellectis S.A. or Coya Therapeutics?
Cellectis S.A. (CLLS) is larger, with a market capitalization of $125.90M compared with $117.05M for Coya Therapeutics (COYA).
Which stock has performed better over the past year, CLLS or COYA?
COYA returned -20.92% over the past 12 months, compared with -70.93% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and Coya Therapeutics in the same industry?
No. Cellectis S.A. is in the Health Care sector, while Coya Therapeutics is in Healthcare.